InsideArbitrage Event Driven Monitor – August 6, 2025

Merger Arbitrage

1. YMAB: The acquisition of Y-mAbs Therapeutics, Inc. (YMAB) by SERB Pharmaceuticals for a closing value of $412 million. SERB will commence an all-cash tender offer to purchase all outstanding shares of Y-mAbs common stock. Holders of Y-mAbs common stock would receive $8.60 per share in cash, representing a premium of 105.25% from the stock’s last close. (Press Release)
2. VRNA: Verona Pharma (VRNA) filed the preliminary proxy statement for its acquisition by Merck (MRK). The company expects the merger to be completed in the fourth quarter of 2025.
3. MTAL: MAC Copper (MTAL) announced that the Court Sanction Hearing is scheduled for October 9, 2025. Also, the implementation date for the merger is set as October 24, 2025.

You can check out new deals, all deal updates, and spreads on active deals in our Merger Arbitrage Tool for premium members here.

Only plus or premium subscribers can access this post. Subscribe today.